Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · IEX Real-Time Price · USD
18.38
-1.00 (-5.16%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Edgewise Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
88
Market Cap
1.72B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.62B |
| National HealthCare | 1.17B |
| Harmony Biosciences Holdings | 617.51M |
| Veracyte | 375.47M |
| Zai Lab | 291.07M |
| Immunocore Holdings | 264.25M |
| Keros Therapeutics | 234.00K |
EWTX News
- 7 weeks ago - Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 - Business Wire
- 7 weeks ago - Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors - Business Wire
- 2 months ago - Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
- 2 months ago - Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies - Business Wire
- 2 months ago - Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) - Business Wire
- 3 months ago - Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session - Business Wire
- 3 months ago - Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 - Business Wire